ArticleAmerican journal of cancer research2023

A multicenter real-world study comparing the clinical equivalence of trastuzumab biosimilar HLX02 and reference trastuzumab in the treatment of HER-2-positive breast cancer.

Weishang Deng et al.PubMed ↗Full text ↗

No numbers read from the abstract.